Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06619561 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
A Phase 2 study of Chronic Graft-versus-host Disease (cGVHD), sponsored by Deciphera Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 20
- Study locations
NCT06619561: Recruiting Phase 2 study of Chronic Graft-versus-host Disease (cGVHD), sponsored by Deciphera Pharmaceuticals.
NCT06619561 is a Phase 2 study of Chronic Graft-versus-host Disease (cGVHD) that is actively recruiting participants, run by Deciphera Pharmaceuticals. The registered enrollment target is 48 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06619561, a Phase 2 study of Chronic Graft-versus-host Disease (cGVHD), is actively recruiting participants, sponsored by Deciphera Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.
Primary Outcome
DLTs assessed for each dose level.
Conditions Studied
Interventions
- DRUG Vimseltinib
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- Ronald Regan UCLA Medical Center - Los Angeles
- University of California Irvine Health - Orange
Ohio
- Oncology Hematology Care Clinical Trials, LLC - Cincinnati
- Cleveland Clinic - Cleveland
- The Ohio State University Comprehensive Cancer Center - Columbus
Florida
- AdventHealth Orlando - Orlando
- Moffitt Cancer Center - Tampa
North Carolina
- Levine Cancer Institute - Charlotte
- Duke University Hospital - Durham
Georgia
- Emory University Winship Cancer Institute - Atlanta
Illinois
- University of Illinois Medical Center - Hematology & Oncology - Chicago
Kansas
- University of Kansas Cancer Center-Westwood - Westwood
Kentucky
- University of Kentucky Markey Cancer Center - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2024-11-21 |
| Est. Completion | 2029-10 |
| Phase | Phase 2 |
What NCT06619561 shows while recruiting
NCT06619561 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Chronic Graft-versus-host Disease (cGVHD) appearing as the primary indexed condition, and to 1 intervention - of which Vimseltinib is the first listed.
NCT06619561 names 20 study sites across 14 states, led by California, Ohio, Florida.
Frequently Asked Questions
What is clinical trial NCT06619561 about?
NCT06619561 is a clinical study titled "A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)". The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.
What is the current status of trial NCT06619561?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2024-11-21. Estimated completion is 2029-10.
What conditions does trial NCT06619561 study?
This clinical trial studies the following conditions: Chronic Graft-versus-host Disease (cGVHD).
What interventions are being tested in trial NCT06619561?
The interventions under investigation include: Vimseltinib (DRUG).
Who is sponsoring clinical trial NCT06619561?
This trial is sponsored by Deciphera Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06619561 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Graft-versus-host Disease (cGVHD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06619561's enrollment target sits among peer trials
48 1265th of 2000 higher than 719 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI